A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.
← catalyst calendarNCT07743944 · readout in 1,811 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
2,000estimated
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-05 | estimated | When the study began enrolling |
| Primary completion | 2031-08-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-08-04 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Primary outcomes
what the primary-completion date above is the date OFPercentage of patients receiving different regimens in each Line of treatment (LoT)
measured From baseline up to 5 years
Percentage of participants receiving different treatment sequence across LoTs
measured From baseline up to 5 years
The attrition rate after each Line of Treatment (LoT)
measured From baseline up to 5 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed